Minghui Pharmaceutical Advances Thyroid Eye Disease Treatment with FDA Approval for Phase Ⅲ Trials Minghui Pharmaceutical has received FDA clearance to start global Phase Ⅲ trials for MHB018A, a new treatment for thyroid eye disease. This innovative therapy shows promising benefits.

Minghui Pharmaceutical Advances Thyroid Eye Disease Treatment with FDA Approval for Phase Ⅲ Trials #China #Shanghai #Minghui_Pharmaceutical #Thyroid_Eye_Disease #MHB018A

Minghui Pharmaceutical Secures $131 Million Pre-IPO Funding to Propel Global Expansion Minghui Pharmaceutical has announced the successful closing of $131 million in Pre-IPO financing to enhance their clinical programs and global reach.

Minghui Pharmaceutical Secures $131 Million Pre-IPO Funding to Propel Global Expansion #China #Shanghai #Minghui_Pharmaceutical #Qiming_Venture_Partners #OrbiMed

Minghui Pharmaceutical Advances Development of Cancer Therapies with New Clinical Trial Initiation Minghui Pharmaceutical commences Phase Ⅱ trial for new combination therapy targeting advanced non-small cell lung cancer (NSCLC) patients, showcasing innovative approaches in cancer treatment.

Minghui Pharmaceutical Advances Development of Cancer Therapies with New Clinical Trial Initiation #China #Shanghai #Minghui_Pharmaceutical #NSCLC #PD-1xVEGF

Minghui Pharmaceutical Partners with Qilu for Oncology Development in Greater China Minghui Pharmaceutical has announced a strategic partnership with Qilu Pharmaceutical to develop the promising B7-H3 ADC therapy across Greater China, highlighting their commitment to cancer innovation.

Minghui Pharmaceutical Partners with Qilu for Oncology Development in Greater China #China #Shanghai #Minghui_Pharmaceutical #Qilu_Pharmaceutical #B7-H3_ADC

Minghui Pharmaceutical Reports Promising Results for New Atopic Dermatitis Ointment in Phase Ⅲ Trial Minghui Pharmaceutical announced positive results in a Phase Ⅲ trial of MH004, an innovative ointment for treating mild to moderate atopic dermatitis, showcasing a significant improvement in patient outcomes.

Minghui Pharmaceutical Reports Promising Results for New Atopic Dermatitis Ointment in Phase Ⅲ Trial #Shanghai #Minghui_Pharmaceutical #MH004 #Atopic_Dermatitis